Scrutiny of Gene Therapy Evidence Intensifies After Recent Setbacks
A series of recent FDA regulatory decisions is sharpening focus on the evidentiary standards underpinning cell and gene therapy development, as sponsors face increasing difficulty translating early promise into approvable data packages — an issue highlighted in a recent opinion piece by Jenna DiRito, co-founder and chief operating officer of Revalia Bio.
An agency complete response letter (see story) for Regenxbio’s RGX-121 has become a focal point for the debate. Despite years of regulatory interaction and encouraging preclinical findings, FDA reviewers ultimately concluded that the application did not meet approval standards, citing concerns tied less to safety than to the robustness and clinical relevance of the efficacy evidence. In particular, the agency questioned the use of an unvalidated biomarker as a primary endpoint and reliance on an external natural history control, according to the opinion piece published on BioSpace.com.
The decision reflects a broader pattern across advanced therapeutics. While some gene therapies — such as Elevidys from Sarepta Therapeutics — have secured approval, others including Roctavian from BioMarin Pharmaceutical and programs like AT132 from Astellas Pharma and SGT-001 from Solid Biosciences have encountered regulatory or clinical setbacks late in development, DiRito wrote.
From a regulatory perspective, these mixed outcomes point to a more fundamental issue: the degree to which early-stage biological evidence can reliably predict clinical benefit. FDA reviewers are increasingly emphasizing that surrogate endpoints, biomarkers and small, uncontrolled datasets must be convincingly linked to meaningful patient outcomes — particularly when therapies are intended to produce durable or irreversible biological effects, the opinion piece argued.
Gene and cell therapies pose distinct challenges for regulators. Their mechanisms — ranging from viral vector delivery to in vivo gene editing — introduce variability tied to immune response, tissue targeting and long-term expression. These factors complicate both trial design and data interpretation, raising the evidentiary bar for demonstrating safety and efficacy, according to DiRito.
The RGX-121 review illustrates how these concerns manifest in practice. Rather than identifying a clear absence of biological activity, FDA’s critique centered on whether the selected endpoints and study design could substantiate clinical benefit. Such cases underscore a recurring regulatory theme: trials may be technically successful yet still fail to provide the level of evidence required for approval, as described in the opinion article.
At the same time, FDA has signaled openness to innovative approaches, including external controls and adaptive trial designs, particularly in rare diseases. However, recent decisions suggest that this flexibility is contingent on the underlying data being sufficiently robust and interpretable. Inconsistent application across programs has fueled industry concern about regulatory predictability, though agency officials have framed the issue as case-specific rather than a shift in policy, DiRito noted.
Recent actions — including the earlier rejection of Roctavian, the CRL for RGX-121 and continued scrutiny of Elevidys — indicate that FDA is placing greater weight on the quality and validation of early evidence, especially where long-term outcomes remain uncertain. For therapies with potentially permanent effects, regulators appear to be applying a more conservative risk-benefit assessment, according to the opinion piece.
In response, sponsors are exploring ways to strengthen the evidentiary foundation before entering clinical trials. Approaches gaining traction include the use of human-relevant models such as organoids, organ-on-chip systems and ex vivo tissues, alongside computational methods that integrate large-scale biological datasets. The aim is to improve the predictive value of preclinical findings and reduce uncertainty carried into late-stage development, DiRito wrote.
For FDA, the trend reinforces a central regulatory challenge: balancing expedited access to transformative therapies with the statutory requirement to ensure substantial evidence of effectiveness. As gene therapies become more complex, the agency’s recent decisions suggest that earlier-stage data — once sufficient to justify advancement — may no longer meet the threshold for approval without clearer demonstration of clinical relevance.
Taken together, the latest wave of setbacks signals not a retreat from innovation, but a recalibration of evidentiary expectations. For developers, aligning early research with FDA’s evolving standards may prove critical to avoiding late-stage regulatory failures, the opinion piece concluded.